Antagonist-mediated down-regulation of toll-like receptors increases the prevalence of human papillomavirus infection in systemic lupus erythematosus
暂无分享,去创建一个
S. Ho | C. Szeto | P. Chan | M. Wong | T. Cheung | S. Yim | L. Tam | E. Li | C. Wong | A. C. Yeung | Shui-Lian Yu | Karine So | M. M. Yu | J. L. Cheung | M. Yu | May M.Y. Yu
[1] P. Boor,et al. Prednisolone Suppresses the Function and Promotes Apoptosis of Plasmacytoid Dendritic Cells , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[2] S. Ho,et al. Risk factors for squamous intraepithelial lesions in systemic lupus erythematosus: A prospective cohort study , 2011, Arthritis care & research.
[3] P. Chan,et al. Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: association with human papillomavirus infection. , 2004, Arthritis and rheumatism.
[4] D. Symmons,et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. , 1996, Arthritis and rheumatism.
[5] T. Iftner,et al. TLR9 Expression and Function Is Abolished by the Cervical Cancer-Associated Human Papillomavirus Type 161 , 2007, The Journal of Immunology.
[6] G. Sen,et al. Interferon‐inducible protein, P56, inhibits HPV DNA replication by binding to the viral protein E1 , 2008, The EMBO journal.
[7] P. Chan,et al. Biases in human papillomavirus genotype prevalence assessment associatedwith commonly used consensus primers , 2006, International journal of cancer.
[8] S. Melgar,et al. Intra-colonic administration of the TLR7 agonist R-848 induces an acute local and systemic inflammation in mice. , 2008, Biochemical and biophysical research communications.
[9] C. Szeto,et al. Down-Regulated NOD2 by Immunosuppressants in Peripheral Blood Cells in Patients with SLE Reduces the Muramyl Dipeptide-Induced IL-10 Production , 2011, PloS one.
[10] V. Preedy,et al. Prospective Cohort Study , 2010 .
[11] C. Bruggeman,et al. The type I interferon response during viral infections: a “SWOT” analysis , 2011, Reviews in medical virology.
[12] H. Amano,et al. Role of pathogenic auto-antibody production by Toll-like receptor 9 of B cells in active systemic lupus erythematosus. , 2007, Rheumatology.
[13] B. Jasani,et al. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer. , 2009, Vaccine.
[14] L. Tam,et al. Immunopathological Roles of Cytokines, Chemokines, Signaling Molecules, and Pattern-Recognition Receptors in Systemic Lupus Erythematosus , 2012, Clinical & developmental immunology.
[15] C. Woodworth,et al. Papillomavirus Type 16 Oncogenes Downregulate Expression of Interferon-Responsive Genes and Upregulate Proliferation-Associated and NF-κB-Responsive Genes in Cervical Keratinocytes , 2001, Journal of Virology.
[16] M. Shlomchik,et al. Chromatin–IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors , 2002, Nature.
[17] K. Straif,et al. Carcinogenicity of human papillomaviruses. , 2005, The Lancet. Oncology.
[18] P. Chan,et al. Determinants of cervical human papillomavirus infection: differences between high- and low-oncogenic risk types. , 2002, The Journal of infectious diseases.
[19] L. Laimins,et al. Microarray Analysis Identifies Interferon-Inducible Genes and Stat-1 as Major Transcriptional Targets of Human Papillomavirus Type 31 , 2000, Journal of Virology.
[20] M. Petri,et al. Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. , 1991, Arthritis and rheumatism.
[21] N. Khan,et al. Effects of age, gender, and immunosuppressive agents on in vivo toll-like receptor pathway responses. , 2010, Human immunology.
[22] A. Komatsuda,et al. Up‐regulated expression of Toll‐like receptors mRNAs in peripheral blood mononuclear cells from patients with systemic lupus erythematosus , 2008, Clinical and experimental immunology.
[23] M. Wong,et al. Natural History of Cervical Papilloma Virus Infection in Systemic Lupus Erythematosus — A Prospective Cohort Study , 2010, The Journal of Rheumatology.
[24] L. Manzel,et al. Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. , 1998, Journal of immunology.
[25] L. Tam,et al. Effects of inflammatory cytokine IL-27 on the activation of fibroblast-like synoviocytes in rheumatoid arthritis , 2010, Arthritis research & therapy.
[26] J. Huibregtse,et al. The ISG15 Conjugation System Broadly Targets Newly Synthesized Proteins: Implications for the Antiviral Function of ISG15 , 2010, Molecular Cell.
[27] S. Akira,et al. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. , 2011, Immunity.
[28] T. Iftner,et al. Gene expression profiles reveal an upregulation of E2F and downregulation of interferon targets by HPV18 but no changes between keratinocytes with integrated or episomal viral genomes. , 2006, Virology.
[29] M. Hochberg,et al. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.
[30] B. Beutler,et al. Intracellular toll-like receptors. , 2010, Immunity.
[31] Lars Karlsson,et al. TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. , 2007, Inflammation & allergy drug targets.
[32] S. Bae,et al. Prevalence of Human Papilloma Virus Infections and Cervical Cytological Abnormalities among Korean Women with Systemic Lupus Erythematosus , 2010, Journal of Korean medical science.
[33] A. Bowie,et al. Viral evasion and subversion of pattern-recognition receptor signalling , 2008, Nature Reviews Immunology.
[34] T. Iftner,et al. High-Risk Human Papillomaviruses Repress Constitutive Kappa Interferon Transcription via E6 To Prevent Pathogen Recognition Receptor and Antiviral-Gene Expression , 2011, Journal of Virology.
[35] L. Tam,et al. Activation profile of Toll‐like receptors of peripheral blood lymphocytes in patients with systemic lupus erythematosus , 2010, Clinical and experimental immunology.
[36] David R. Scott,et al. Improved Amplification of Genital Human Papillomaviruses , 2000, Journal of Clinical Microbiology.
[37] M. V. Van Beek,et al. Antimalarials , 2001, Dermatologic clinics.
[38] Xuejun Liu,et al. Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli. , 2004, The Journal of clinical investigation.
[39] G. Karypis,et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus , 2003, Proceedings of the National Academy of Sciences of the United States of America.